Elevated interleukin-6 secretion levels by mononuclear cells of Alzheimer's patients
Abstract
It has been suggested in recent research that interleukin-1 (IL-1) and interleukin-6 (IL-6) play a role in the pathogenesis of Alzheimer's disease (AD). Production of IL-1, by lipopolysaccharide (LPS)-stimulated monocytes, and IL-6, by phytohaemagglutinin (PHA)-stimulated mononuclear cells, was assessed in patients with AD divided into two groups--mild and moderately severe--according to severity of disease, and elderly controls. No differences in IL-1 production were found among AD patients and controls. However, significant elevation in IL-6 secretion levels was observed in both the mild and moderately severe AD patients. Our results suggest that peripheral IL-6 secretion levels may be responsible for acute-phase proteins observed in the serum of AD patients.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There is some evidence of elevated IL-6 levels in monocytes derived from AD patients.
“In fact, there is some evidence of elevated IL-6 levels in monocytes derived from AD patients [154–156].”
From PKR, the double stranded RNA‐dependent protein kinase as a critical target in Alzheimer's disease (2009) · cites this paper as [155]
Cites
The decrease of CD8-positive lymphocytes in Alzheimer's disease
Pirttilä, T., Mattinen, S., & Frey, H. (1992) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(92)90284-r · Cited by 72 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Age-Associated Increased Interleukin-6 Gene Expression, Late-Life Diseases, and Frailty
Ershler, W. B., & Keller, E. T. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.245 · Cited by 1,282 · see citing works
Age-related inflammatory cytokines and disease
Brüünsgaard, H., & Pedersen, B. K. (2003) · Immunology and Allergy Clinics of North America · doi:10.1016/s0889-8561(02)00056-5 · Cited by 608 · see citing works
Neuroinflammation: Implications for the Pathogenesis and Molecular Diagnosis of Alzheimer's Disease
Rojo, L. E., Fernández, J. A., Maccioni, A. A., Jimenez, J. M., & Maccioni, R. B. (2008) · Archives of Medical Research · doi:10.1016/j.arcmed.2007.10.001 · Cited by 351 · see citing works
Oxidative stress and β-amyloid protein in Alzheimer’s disease
Cai, Z., Zhao, B., & Ratka, A. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8155-9 · Cited by 279 · see citing works
T-Cells in Alzheimer's Disease
Town, T., Tan, J., Flavell, R. A., & Mullan, M. (2005) · NeuroMolecular Medicine · doi:10.1385/nmm:7:3:255 · Cited by 183 · see citing works
Blood levels of histamine, IL-1β, and TNF-α in patients with mild to moderate alzheimer disease
Alvarez, X. A., Franco, A., Fernández-Novoa, L., & Cacabelos, R. (1996) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815005 · Cited by 139 · see citing works
Suo, Z., Tan, J., Placzek, A., Crawford, F., Fang, C., & Mullan, M. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00780-x · Cited by 116 · see citing works
Expression of CAP37, a Novel Inflammatory Mediator, in Alzheimer's Disease
Pereira, H. (1996) · Neurobiology of Aging · doi:10.1016/s0197-4580(96)00118-2 · Cited by 62 · see citing works
PKR, the double stranded RNA‐dependent protein kinase as a critical target in Alzheimer's disease
Morel, M., Couturier, J., Lafay‐Chebassier, C., Paccalin, M., & Page, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00849.x · Cited by 47 · see citing works
- Authors
- Shalit, F., Sredni, B., Stern, L., Kott, E., & Huberman, M.
- Affiliations
- Bar-Ilan University (IL)
- Tel Aviv University (IL)
- Corresponding author
- Huberman, M.
- ORCID
- Sredni, B.
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 1994-06
- Volume
- 174
- Issue
- 2
- Pages
- 130-132
- ISSN
- 0304-3940 (ISSN-L)
- OpenAlex
- W2066160540
- Cited by
- 54
- References
- 1
- Citations by year
- 2024: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 2 · 2016: 2 · 2014: 4 · 2013: 1 · 2012: 1
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuroscience Letters (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, interleukin-6, interleukin-1, mononuclear cells, monocytes, acute phase proteins, disease severity, neuroinflammation
- MeSH terms
- Aged, Alzheimer Disease, Female, Humans, Interleukin-1, Lipopolysaccharides, Male, Monocytes, Phytohemagglutinins, Interleukin-6, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
